Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024.
- Second-quarter revenues decreased to $241 million from $344 million in the prior-year period
- Net loss narrowed to $1.28 billion or $3.33 per share in Q2 from $1.38 billion or $3.62 per share a year earlier
- Net product sales for the quarter were $184 million, reflecting a 37% decrease from the same period in 2023
- For fiscal 2024, the company expects total product sales to be between $3.0 billion and $3.5 billion
- Full-year cost of sales is expected to be in the range of 40-50% of product sales
- Q2 cost of sales was $115 million, including third-party royalties unutilized manufacturing capacity & wind-down costs, and inventory write-downs
- Cash, cash equivalents, and investments as of June 30, 2024, were $10.8 billion, vs. $12.2 billion as of March 31, 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
